RxDoctor Payments Data

Kristin Corapi, MD

Nephrology · Boston, MANPI 1295982007

Payments from drug & device makers

$11,412in general payments, 2019–2025

Across 21 payments — averaging $543.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Travere Therapeutics, Inc.$7K
  • Fresenius USA Marketing, Inc.$4K
  • Nxstage Medical, Inc.$744
  • Bayer$20
  • AstraZeneca$16

What the payments were for

  • Consulting fees$2,40049%
  • Travel & lodging$1,15223%
  • Food & beverage$1,35828%
  • Education$30%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,412 in reported general payments places this provider in the 75th percentile of 339 nephrology providers in Massachusetts.

See all nephrology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$132,637
Medicare patients
319
Services billed
1,885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin97$110,659
FarxigaDapagliflozin Propanediol13$21,257
Sevelamer Carbonate59$15,103
LokelmaSodium Zirconium Cyclosilicate12$11,269
Candesartan Cilexetil69$7,432
Bumetanide68$3,352
Lisinopril322$2,992
ClinolipidFat Emulsion/Olive/Soy/Phospho14$2,738
Amlodipine Besylate248$2,415
Furosemide295$2,281
Chlorthalidone100$2,191
Calcium Acetate20$2,162
Metoprolol Succinate84$2,062
Sodium Polystyrene Sulfonate32$2,014
Olmesartan Medoxomil36$1,718

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$16$32,52625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 339 nephrology providers in Massachusetts.

Other nephrology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →